JP2022533009A5 - - Google Patents

Info

Publication number
JP2022533009A5
JP2022533009A5 JP2021564299A JP2021564299A JP2022533009A5 JP 2022533009 A5 JP2022533009 A5 JP 2022533009A5 JP 2021564299 A JP2021564299 A JP 2021564299A JP 2021564299 A JP2021564299 A JP 2021564299A JP 2022533009 A5 JP2022533009 A5 JP 2022533009A5
Authority
JP
Japan
Prior art keywords
composition according
seq
immune complex
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021564299A
Other languages
English (en)
Japanese (ja)
Other versions
JP7585231B2 (ja
JP2022533009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/030478 external-priority patent/WO2020223351A1/en
Publication of JP2022533009A publication Critical patent/JP2022533009A/ja
Publication of JP2022533009A5 publication Critical patent/JP2022533009A5/ja
Priority to JP2024193438A priority Critical patent/JP2025023995A/ja
Application granted granted Critical
Publication of JP7585231B2 publication Critical patent/JP7585231B2/ja
Priority to JP2026052973A priority patent/JP2026108789A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021564299A 2019-04-29 2020-04-29 抗cd123免疫複合体を含む治療的組み合わせ Active JP7585231B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024193438A JP2025023995A (ja) 2019-04-29 2024-11-05 抗cd123免疫複合体を含む治療的組み合わせ
JP2026052973A JP2026108789A (ja) 2019-04-29 2026-03-26 抗cd123免疫複合体を含む治療的組み合わせ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962839974P 2019-04-29 2019-04-29
US62/839,974 2019-04-29
US201962860598P 2019-06-12 2019-06-12
US62/860,598 2019-06-12
PCT/US2020/030478 WO2020223351A1 (en) 2019-04-29 2020-04-29 Therapeutic combinations comprising anti-cd123 immunoconjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024193438A Division JP2025023995A (ja) 2019-04-29 2024-11-05 抗cd123免疫複合体を含む治療的組み合わせ

Publications (3)

Publication Number Publication Date
JP2022533009A JP2022533009A (ja) 2022-07-21
JP2022533009A5 true JP2022533009A5 (cg-RX-API-DMAC7.html) 2023-04-13
JP7585231B2 JP7585231B2 (ja) 2024-11-18

Family

ID=73029177

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021564299A Active JP7585231B2 (ja) 2019-04-29 2020-04-29 抗cd123免疫複合体を含む治療的組み合わせ
JP2024193438A Pending JP2025023995A (ja) 2019-04-29 2024-11-05 抗cd123免疫複合体を含む治療的組み合わせ
JP2026052973A Pending JP2026108789A (ja) 2019-04-29 2026-03-26 抗cd123免疫複合体を含む治療的組み合わせ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024193438A Pending JP2025023995A (ja) 2019-04-29 2024-11-05 抗cd123免疫複合体を含む治療的組み合わせ
JP2026052973A Pending JP2026108789A (ja) 2019-04-29 2026-03-26 抗cd123免疫複合体を含む治療的組み合わせ

Country Status (12)

Country Link
US (2) US11701428B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962528A4 (cg-RX-API-DMAC7.html)
JP (3) JP7585231B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004669A (cg-RX-API-DMAC7.html)
CN (1) CN113853217A (cg-RX-API-DMAC7.html)
AU (1) AU2020265225B2 (cg-RX-API-DMAC7.html)
CA (1) CA3137454A1 (cg-RX-API-DMAC7.html)
IL (1) IL287446A (cg-RX-API-DMAC7.html)
MA (1) MA55816A (cg-RX-API-DMAC7.html)
SG (1) SG11202110702WA (cg-RX-API-DMAC7.html)
TW (1) TWI865521B (cg-RX-API-DMAC7.html)
WO (1) WO2020223351A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7585231B2 (ja) 2019-04-29 2024-11-18 イミュノジェン, インコーポレイテッド 抗cd123免疫複合体を含む治療的組み合わせ
BR112023023677A2 (pt) * 2021-05-11 2024-02-20 Abbvie Inc Regimes de dosagem de venetoclax para o uso no tratamento de síndromes mielodisplásicas em combinação com azacitidina
TW202423485A (zh) * 2022-12-08 2024-06-16 美商伊繆諾金股份有限公司 包含抗cd123抗體-藥物結合物及抗cd47抗體之治療組合
WO2025235924A2 (en) * 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
US9011864B2 (en) * 2007-12-26 2015-04-21 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
WO2012142411A1 (en) * 2011-04-15 2012-10-18 Clavis Pharma Asa Systems and methods for detecting hent1 expression in hematological disorders
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Cd123抗體及其共軛物
SI3313845T1 (sl) 2015-06-29 2021-01-29 Immunogen, Inc. Konjugati spremenjenih protiteles cisteina
SMT202100092T1 (it) * 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
CA3002029A1 (en) * 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
BR112018008882A8 (pt) * 2015-11-03 2019-02-26 Univ Texas método para tratar um distúrbio proliferativo e produto farmacêutico
RS65120B1 (sr) 2015-11-25 2024-02-29 Immunogen Inc Farmaceutske formulacije i postupci za njihovu upotrebu
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
EP3544983A2 (en) 2016-11-23 2019-10-02 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
EP3630839A1 (en) * 2017-06-01 2020-04-08 Xencor, Inc. Bispecific antibodies that bind cd 123 cd3
GB2567613A (en) * 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
WO2018236904A1 (en) * 2017-06-19 2018-12-27 Surface Oncology, Inc. COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
IL271946B (en) * 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
JP2020528061A (ja) * 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
TWI826393B (zh) 2017-09-22 2023-12-21 美商免疫遺傳股份有限公司 使用陽離子交換層析法分離三輕鏈抗體
CN111372610B (zh) 2017-09-22 2023-05-30 伊缪诺金公司 防止免疫结合物中的甲硫氨酸氧化的方法
WO2020092533A2 (en) * 2018-10-30 2020-05-07 Immunogen, Inc. Methods of treatment using anti-cd123 immunoconjugates
US20210393791A1 (en) * 2018-10-31 2021-12-23 Health Research, Inc. Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor
JP7585231B2 (ja) * 2019-04-29 2024-11-18 イミュノジェン, インコーポレイテッド 抗cd123免疫複合体を含む治療的組み合わせ

Similar Documents

Publication Publication Date Title
JP7822424B2 (ja) 急性骨髄性白血病治療のための抗-cd70抗体argx-110の使用
DeAngelo et al. Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
JP2005533001A5 (cg-RX-API-DMAC7.html)
CN103282050A (zh) 包含特异性识别cd38的抗体和硼替佐米的抗肿瘤组合
CN110381938A (zh) 减少中性粒细胞缺乏症的方法
JP2022058676A (ja) Liv1-adc及び化学療法剤を用いた併用療法
JP2022553293A5 (cg-RX-API-DMAC7.html)
CN110785184A (zh) 用于治疗癌症的方法,组合物和试剂盒
JP2022513405A5 (cg-RX-API-DMAC7.html)
Brethon et al. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg®) in children with relapsed/refractory myeloid leukemia
TW202207976A (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2017515843A5 (cg-RX-API-DMAC7.html)
WO2021213523A1 (zh) 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
CN121548431A (zh) 包含偶联物的药物组合的治疗方法和用途
EP4735037A1 (en) Combination therapies for the treatment of non-small cell lung cancer
JP2026516281A (ja) Cd20発現b細胞癌の治療方法
CN121443321A (zh) 治疗组合及其用途和治疗方法
WO2024026019A1 (en) Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies
JP7705353B2 (ja) Cd38抗体を使用する併用療法
CN119031933B (zh) 蛋白酶体抑制剂与抗pd-1抗体的药物组合
US20250019441A1 (en) Treatment of cancer with anti-ilt2 antibodies
KR20200105825A (ko) 삼중 음성 유방암의 치료를 위한 pd-1 항체 및 아파티닙의 조합 치료의 용도
RU2021130429A (ru) Терапевтические комбинации, содержащие иммуноконъюгаты anti-cd123
HK40112285A (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
WO2023030532A1 (zh) 用于治疗食管癌的药物组合